期刊文献+

吉非替尼治疗晚期非小细胞肺癌不良反应的观察及处理 被引量:11

下载PDF
导出
摘要 目的对晚期非小细胞肺癌患者应用吉非替尼后的不良反应进行观察和统计。方法选择44例晚期非小细胞肺癌患者,应用吉非替尼治疗90 d后,对其不良反应进行观察和统计。结果不良反应有皮疹20例(45%),腹泻9例(20%),皮肤瘙痒6例(14%),胃肠道反应6例(14%),肝功能异常4例(9%),间质性肺炎1例(2%)。结论患者服用药物期间,重视药物的不良反应,加强观察和护理,对不良反应要给予及时有效治疗和护理,提高治疗依从性和舒适度,改善患者的生活质量。
作者 黄小珍
出处 《现代中西医结合杂志》 CAS 2013年第1期96-97,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献7

二级参考文献93

  • 1陈智伟,廖美琳,陈玉蓉,赵家美,张心敏,成柏君.WHO标准和RECIST标准评价肺癌化疗疗效的比较[J].循证医学,2004,4(2):83-84. 被引量:34
  • 2王彬,张湘茹,储大同.易瑞沙在晚期非小细胞肺癌化疗失败后的作用[J].中华肿瘤杂志,2004,26(12):742-745. 被引量:53
  • 3张康,左强,罗荣城.吉非替尼治疗36例晚期非小细胞肺癌[J].中国癌症杂志,2006,16(10):878-879. 被引量:15
  • 4唐涛,费素娟.NF-κB与胃癌关系的研究进展[J].国际消化病杂志,2006,26(5):296-299. 被引量:10
  • 5Kim MA,Lee HS.EGFR in gastric carcinomas:prognostic significance of protein overexpression and high gene copy number[J].Histopathology,2008,52 (6):738-746.
  • 6Adelstein DJ,Bybicki LA,Carroll MA,et al.Phase Ⅱ trial of gefitinib for recurrent or metastatic esophageal or gastroe-sophageal junction(GEJ) cancer[J].J Clin Oncol(Meeting Abstracts),2005,23(16):4054.
  • 7Dragovich T,McCoy S,Feniglio-Preiser CM,et al.Phase Ⅱ trial of erlotinib in gastroesophageal junction and gastric adenocarcinoma:SWOG 0127[J].J Clin Oncol,2006,24:4922-4927.
  • 8Kanzler S,Trarbach T,Seufferlein T,et al.Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer:A nonrandomized multicenter AIO phase Ⅱ study[J].ASCO Meeting,2009,27:a4534.
  • 9Woell E,Greil R,Eisterer W,et al.Oxaliplatin,irinotecan,and ceruximab in advanced gastric cancer.First efficacy results of a multicenter phase Ⅱ trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT)[J].ASCO Meeting,2009,27:a4538.
  • 10Yen K,Hsu C,Lin C,et al.Phase Ⅱ study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer[J].ASCO Meeting,2009,27:a4567.

共引文献116

同被引文献121

  • 1顾爱琴,高志强,王慧敏,施春雷,熊丽纹,韩宝惠.吉非替尼单药治疗晚期非小细胞肺癌老年患者的临床分析[J].上海交通大学学报(医学版),2011,31(3):305-308. 被引量:23
  • 2柴红,陈泽泉,余永利.甲状腺髓样癌靶向治疗新进展[J].上海交通大学学报(医学版),2011,31(10):1470-1474. 被引量:3
  • 3王晓光,李金瀚,罗荣城.培美曲塞治疗非小细胞肺癌临床研究进展[J].中国肺癌杂志,2005,8(3):254-256. 被引量:16
  • 4杨文东,彭伟强,李勇生,黄宇康.电视胸腔镜在早期周围型肺癌手术中的应用[J].现代中西医结合杂志,2005,14(16):2095-2096. 被引量:1
  • 5吴洪斌.吉非替尼不良反应的临床表现及其处理[J].药物不良反应杂志,2006,8(1):28-30. 被引量:44
  • 6Scagliotti GV,Parikh P,Von Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naive patients with advancedstage non small cell lung cancer[J].J Clin Oncolm,2008,26(21):3543-3551.
  • 7Calvert H.An overview of folate metabolism:features relevant to the action and toxicities of antifolate anticancer agents[J].Semi Oncol,2005,26(Suppl):3-10.
  • 8Hardy D,Cormier JN,Xing Y,et al. Chemotherapy- associated toxicity in a large cohort of elderly pa- tients with non-small cell lung cancer[J]. J Thorac Oncol,2010,5(1) :90--98.
  • 9Wu CH, Fan WC, Chen YM, et al. Second-line ther- apy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effec- tive as for younger patients. J Thorac Oncol, 2010,5(3) : 376--379.
  • 10Han K, Cao W, Che J, et al. First line chemotherapy with weekly docetaxel and cisplatin in elderly pa- tients with advanced non-small cell lung cancer., a multicenter phase II study[J]. J Thorac Oncol, 2009,4(4) :512-- 517.

引证文献11

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部